NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee B meeting minutes

**Minutes:** Confirmed

**Date and time:** Thursday 9 September 2021

**Location:** Zoom

## Attendees

Committee members present

1. Professor Amanda Adler (Chair) Present for all items
2. Dr Sanjeev Patel (Vice Chair) Present for all items
3. Ms Anna Pracz Present for all items
4. Ms Denise Bryceland Present for all items
5. Mr Gabriel Rogers Present for all items
6. Professor Iolo Doull Present for items 5 to 6.2
7. Dr James Fotheringham Present for all items
8. Dr Laura Bojke Present for items 1 to 5
9. Ms Maria Bretzitski Present for all items
10. Ms Mary Weatherstone Present for all items
11. Dr Nicholas Latimer Present for all items
12. Mr Nigel Westwood Present for all items
13. Mr Peter Wheatley Price Present for all items
14. Dr Rhiannon Owen Present for all items
15. Dr Stephen Smith Present for all items
16. Dr Stuart Williams Present for items 1 to 6
17. Mr Toby Smith Present for all items
18. Mr Tony Wootton Present for all items

NICE staff present

Nicole Elliott, Associate director Present for items 1 to 4 and 6 to 7

Henry Edwards, Associate director Present for items 5 to 6

Shonagh D’Slyva, Project manager Present for items 5 to 6

Adam Brooke, Technical advisor Present for items 1 to 5

Catherine Pank, Assistant project manager Present for items 1 to 4 and 6 to 7

Elizabeth Bell, Technical lead Present for items 1 to 5

Ella Livingstone, Technical adviser Present for items 1 to 5

Emilene Coventry, Senior medical editor Present for items 1 to 5

Emma Gordon, Administrator Present for items 1 to 4 and 6 to 7

Heidi Livingstone, Senior Present for items 1 to 4.2

public involvement officer

James Devine, Coordinator Present for all items

Jamie Jason, Coordinator Present for items 1 to 6

Lucy Ingram, Administrator Present for items 5 to 6

Philip Williams, Finance/Business Analyst Present for all items

Rosalee Mason, Coordinator Present for items 1 to 4.2, 5 to 5.2

and 6 to 6.2

Sophie McHugh, Administrator Present for all items

Eleanor Donegan, Technical adviser Present for items 5 to 6

Harisman Serpal, Technical lead Present for items 5 to 6

Aminata Thiam, Technical lead Present for items 6 to 7

Yelan Guo, Technical advisor Present for items 6 to 7

Stevie Okoro, Technical analyst Present for items 5 to 6

Bryn White, Project manager Present for items 5 to 6

Benjamin Pearce, Senior medical editor Present for items 6 to 7

External group representatives present

Professor G.J Melendez, Director,

Peninsula Technology Assessment Group Present for items 1 to 4.3

Mr Brian O’Toole, Research Fellow,

Peninsula Technology Assessment Group Present for items 1 to 4.3

Dr Jo Picot, Senior Research Fellow,

Southampton Health Technology Assessments Centre Present for items 5 to 5.2Professor Professor Joanne Lord, Director,

Southampton Health Technology Assessments Centre Present for items 5 to 5.2

Dr Rob Riemsma, Reviews Manager, Kleijnen Systematic Reviews Present for items 6 to 6.3

Dr Hannah Penton, Health Economics Researcher,

Kleijnen Systematic Reviews Present for items 6 to 6.3

Experts present

Dr Eli Silber, Consultant neurologist, Kings College Hospital

Present for items 1 to 4.2

Mrs Helena Jidborg, Information Content Participation Officer

Multiple Sclerosis Trust and patient with lived experience Present for items 1 to 4.2

Mr Malcolm Qualie, Pharmacy lead, Specialised Commissioning

NHS England and Improvement Present for items 1 to 4.2

Professor Neil Robertson, Professor of Neurology, Cardiff University Present for items 1 to 4.2

Ms Sarah Bittlestone, Patient with lived experience,

nominated by Multiple Sclerosis Society Present for items 1 to 4.2

## Minutes

### Introduction to the meeting

* 1. The chair, Dr Sanjeev Patel, welcomed members of the committee and other attendees present to the meeting.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Wednesday 4 August 2021

### Appraisal of [D1393] Ponesimod for treating relapsing multiple sclerosis

* 1. Part 1 – Open session
     1. The chair, Dr Sanjeev Patel, welcomed the invited professional and patient experts, external group representatives, members of the public and company representatives from Janssen.
     2. The chair, Dr Sanjeev Patel, asked all committee members, experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr James Fotheringham declared a financial interest as he received speaker honoraria and consultancy fees from Novartis for health economic modelling and risk prediction in solid organ transplantation.
* It was agreed that his declaration would not prevent Dr James Fotheringham from participating in this section of the meeting.
* Dr Nick Latimer declared a financial interest as Merck (a comparator company) paid him to present at an ISPOR webinar about methods for modelling treatment sequences in December 2020. His presentation was not drug or disease specific.
* It was agreed that his declaration would not prevent Dr Nick Latimer from participating in this section of the meeting.
* Professor Neil Robertson declared a direct financial interest as he previously received honoraria from Genzyme/Sanofi, Novartis, Abbvie, Biogen, Janssen, Celgene, and AstraZeneca in the last few years. Cardiff University has received support for research projects from NICE and worked with Novartis on a research project entitled ‘The epidemiology of MS in the UK, a joint working project’, which Novartis have funded (£350k) and which ends in December 2021.
* It was agreed that his declaration would not prevent Professor Neil Robertson from participating in this section of the meeting.
* Dr Eli Silber declared a direct financial interest as he has previously received consulting fees and support to attend meetings from Biogen. His unit has also previously received support for service developments from Biogen.
* It was agreed that his declaration would not prevent Dr Eli Silber from participating in this section of the meeting.
  + 1. The Chair, Dr Sanjeev Patel, led a discussion of the evidence presented to the committee. This information was presented to the committee by Anna Pracz, Gabriel Rogers and Nigel Westwood.
  1. Part 2a – Closed session (members of the public, company representative and experts were asked to leave the meeting. External group representatives remained).
     1. The committee discussed confidential information submitted for this item.
  2. Part 2b – Closed session (external group representatives were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with its decisions.

### Appraisal of [ID1213] Dupilumab for treating severe asthma

* 1. Part 1 – Open session
     1. The chair, Dr Sanjeev Patel, welcomed the invited professional experts, external group representatives, members of the public and company representatives from Sanofi.
     2. The chair, Dr Sanjeev Patel, asked all committee members, professional experts, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr James Fotheringham declared a Financial Interest as he received speaker honoraria and consultancy fees from Novartis for health economic modelling and risk prediction in solid organ transplantation.
* It was agreed that his declaration would not prevent Dr James Fotheringham from participating in this section of the meeting.
* Dr Nick Latimer declared a Non-Financial Professional & Personal Interests as he is a member of the ScHARR team for a consultancy project involving the adjustment for treatment switching observed in the NETTER-1 trial, comparing lutathera to best supportive care alone in patients with advanced, progressive, somatostatin-receptor-positive midgut neuroendocrine tumours. Lutathera is made by Advanced Accelerator Applications (AAA) Ltd, a Novartis company. Novartis are listed as a comparator company.
* It was agreed that his declaration would not prevent Dr Nick Latimer from participating in this section of the meeting.
  + 1. The Chair, Dr Sanjeev Patel, led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Sanjeev Patel.
  1. Part 2 – Closed session (company representatives, external group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Appraisal of [ID1599] Nintedanib for treating progressive fibrosing interstitial lung disease excluding idiopathic pulmonary fibrosis

* 1. Part 1 – Open session
     1. The chair, Professor Amanda Adler, welcomed the invited external group representatives, members of the public and company representatives from Boehringer Ingelheim.
     2. The chair, Professor Amanda Adler, asked all committee members, external group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
     3. The chair, Professor Amanda Adler, led a discussion of the evidence presented to the committee. This information was presented to the committee by the chair, Professor Amanda Adler.
  2. Part 2a – Closed session (members of the public and company representatives were asked to leave the meeting. The evidence review group remained).
     1. The committee discussed confidential information submitted for this item.
  3. Part 2b – Closed session (Evidence group representatives were asked to leave the meeting).
     1. The committee then agreed on the content of the Final Appraisal Determination (FAD). The committee decision was reached through a vote by members.
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.

### Date of the next meeting

The next meeting of the Technology Appraisal Committee B will be held on Thursday 7 October 2021 and will start promptly at 9:00am.